Related references
Note: Only part of the references are listed.Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Chung-Han Lee et al.
BRITISH JOURNAL OF CANCER (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Abdallah Flaifel et al.
CLINICAL CANCER RESEARCH (2019)
First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options
Vivian Loo et al.
TARGETED ONCOLOGY (2019)
Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
Carmine D'Aniello et al.
FRONTIERS IN ONCOLOGY (2019)
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K. Choueiri et al.
EUROPEAN JOURNAL OF CANCER (2018)
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M. Tolaney et al.
ONCOLOGIST (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2016)
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
Raya Leibowitz-Amit et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-na < ve patients with metastatic renal cell carcinoma
Charles S. Harmon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Erinn B. Rankin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
G. T. Gibney et al.
ANNALS OF ONCOLOGY (2013)
The VHL/HIF axis in clear cell renal carcinoma
Chuan Shen et al.
SEMINARS IN CANCER BIOLOGY (2013)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Carol Pena et al.
CLINICAL CANCER RESEARCH (2010)
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Loukas F. Kontovinis et al.
BMC CANCER (2009)
Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival
Anna Gustafsson et al.
CLINICAL CANCER RESEARCH (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
Michael L. Nickerson et al.
CLINICAL CANCER RESEARCH (2008)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Share Paper
